From Yahoo Finance: 2025-05-09 12:07:00

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported first-quarter adjusted earnings of $1.70 per share, beating the consensus of $1.38 per share, with sales of $197.12 million, exceeding the consensus of $180.68 million. Net revenues for rare diseases grew 31.7% year-over-year, with Cortrophin Gel net revenues increasing by 43.1% to $52.9 million.

During the quarter, ANI Pharmaceuticals saw increased demand, with the highest number of new patient starts and new cases initiated since launch. Cortrophin Gel, Iluvien, and Yutiq generated net revenues of $16.1 million, while brand net revenues decreased by 2.2% to $25.1 million.

Net revenues for Generic pharmaceutical products increased by 40.5% to $98.7 million, driven by increased volumes and new product launches. Reported gross margin decreased, primarily due to a mix shift towards royalty-bearing products like Cortrophin Gel.

ANI Pharmaceuticals raised its 2025 revenue guidance from $756 million to $776 million to $768 million to $793 million, with adjusted EBITDA expected to be between $195 million to $205 million. CEO Nikhil Lalwani expressed optimism for the company’s performance based on strong demand for their products.



Read more at Yahoo Finance: Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact